Tirzepatide 50mg

Tirzepatide (50 mg) is a synthetic lipidated peptide containing 39 amino acids and a C20 fatty diacid moiety, prepared for controlled laboratory investigation. The tirzepatide peptide is produced via standardized synthesis and purification protocols to support reproducible experimental research in metabolic and endocrine sciences. Laboratories that order tirzepatide peptide in this larger vial size often do so to support extended study designs or repeated assay preparation.

The peptide has a molecular weight of approximately 4.8 kDa and is supplied as a high-purity (≥98%) lyophilized powder in a sealed research-grade vial. This dry format supports long-term stability, transport integrity, and accurate preparation of working solutions for in vitro and preclinical applications.

Published research has examined tirzepatide’s interactions with biological systems involved in energy balance, glucose-related processes, and broader metabolic regulation. These investigations remain focused on laboratory observation and functional analysis rather than clinical interpretation.

• High-purity tirzepatide peptide intended for controlled laboratory research
• Identity and purity verified through quality control testing
• Used in experimental studies of metabolic and endocrine signaling
• Suitable for in vitro and preclinical research models
• Stable formulation under recommended storage conditions
• Compatible with standard laboratory reconstitution techniques
• For laboratory research use only.

Tirzepatide is being examined in laboratory settings for its involvement in metabolic signaling and nutrient response pathways. Research models evaluate their interaction with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor systems to better understand peptide-mediated metabolic behavior.

Experimental applications emphasize system-level observation of energy regulation and glucose handling, using controlled conditions to generate reproducible laboratory data. These studies are designed to clarify peptide behavior rather than to assess therapeutic outcomes.

Laboratory investigations involving the tirzepatide peptide commonly employ nanomolar to micromolar concentrations in cell-based assays. In preclinical research, weight-adjusted dosing protocols may be applied in alignment with the experimental model and study objectives.

Observed effects are documented as changes in metabolic markers, insulin-related activity, or other measurable biological responses specific to the research system used. All findings are reported as experimental observations rather than indicators of efficacy.

All dosing information is provided solely to support research methodology and experimental reproducibility.

Store tirzepatide peptide in its lyophilized form at –20 °C or below, protected from light and moisture. Reconstituted solutions should be prepared using sterile laboratory techniques, stored at 2–8 °C, and used within 72 hours unless stability data indicate otherwise. Avoid repeated freeze–thaw cycles to maintain peptide integrity. Laboratories that buy tirzepatide peptide should adhere to institutional handling and documentation standards.

References

https://www.pnas.org/doi/10.1073/pnas.2116506119

https://pmc.ncbi.nlm.nih.gov/articles/PMC9438179/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9149770/

https://pmc.ncbi.nlm.nih.gov/articles/PMC9396640/

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.